Showing results (131-140 of 175) with videos related to

Sort By:
Pageof 18
Blood Advances|April 12, 2023
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trialsSrdan Verstovsek, Ruben Mesa, Vikas Gupta, et al.
The Journal of Clinical Investigation|November 2, 2023
Targeting lysine demethylase 6B ameliorates ASXL1 truncation-mediated myeloid malignancies in preclinical modelsGuo Ge, Peng Zhang, Pinpin Sui, et al.
Blood Advances|December 21, 2021
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 studyJohn Mascarenhas, Francesco Passamonti, Kate Burbury, et al.
Ejhaem|February 26, 2024
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosisStephen T Oh, Srdan Verstovsek, Vikas Gupta, et al.
JAMA Oncology|March 10, 2018
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical TrialJohn Mascarenhas, Ronald Hoffman, Moshe Talpaz, et al.
Haematologica|May 11, 2023
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trialSrdan Verstovsek, Lynda Foltz, Vikas Gupta, et al.
Blood|May 10, 2007
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelAyalew Tefferi, Juergen Thiele, Attilio Orazi, et al.
EMBO Reports|August 31, 2023
Loss of BRD4 induces cell senescence in HSC/HPCs by deregulating histone H3 clippingHui Yang, Pinpin Sui, Ying Guo, et al.
Haematologica|September 6, 2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsTariq I Mughal, Nicholas C P Cross, Eric Padron, et al.
Blood Advances|May 31, 2024
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosisAaron T Gerds, Claire Harrison, Jean-Jacques Kiladjian, et al.
Pageof 18